Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) headquartered in Tarrytown, will host a conference call for the investment community to discuss the 3Q20 financial results on 5th November 2020 at 8:30 AM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.regeneron.com
Earnings Expectation
Regeneron Pharmaceuticals, Inc. is set to announce third quarter earning results on Thursday 5th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, REGN to report 3Q20 income of $ 7.13 per share. For the full year, analysts anticipate top line of $ 8176.80 million, while looking forward to income of $ 28.75 per share bottom line.
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The companys products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults.
